Bintrafusp alfa, a novel bispecific antibody, achieved an objective response rate of 22% in women with recurrent or metastatic cervical cancer in a phase II nonrandomized controlled trial.
Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.
